Systematic analysis of innovative cancer treatment options and patient survival
9.4.2025
Question for written answer E-001448/2025
to the Commission
Rule 144
Letizia Moratti (PPE)
In the area of scientific research, considerable strides have been made in the development of innovative cancer therapies that offer patients new treatment options. The most notable include: immunotherapy, which attacks cancer cells by means of the patient’s immune system; targeted therapies, which targets the specific genetic mutations in cancer cells; nanomedicine, which delivers drugs directly to cancer cells via nanoparticles; liquid biopsies, which detects circulating tumour cells; advanced therapies with modified cells that accurately combat cancer, also by means of the patient’s immune system.
Those therapies’ success has significantly increased survival rates, but it is difficult for patients to identify and access the most effective treatment, as they lack comparable and best practice data.
In the light of the above:
- 1.Will the Commission build up, coordinate and collect data for a systematic assessment of the effectiveness of innovative cancer therapies, comparing best practices with regard to their outcomes on patient survival and quality of life?
- 2.Will it foster patient access to treatment and related data, possibly through the establishment of a European database, including within the framework of the European Health Data Space?
- 3.Will it support research and the deployment of new technologies to improve the effectiveness of cancer treatments?
Submitted: 9.4.2025